Exenatide vs Syn-Ake
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Syn-Ake
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic tripeptide that mimics the effect of Waglerin-1, a peptide found in Temple Viper venom. It's used in cosmetics for anti-wrinkle effects.
Full details →Side-by-Side Comparison
| Aspect | Exenatide | Syn-Ake |
|---|---|---|
| Mechanism | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. | Acts as a competitive antagonist at the nicotinic acetylcholine receptor, reducing muscle contractions similar to Botox but through a different mechanism. Provides muscle-relaxing effects when applied topically. |
| Typical Dosage | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. | Topical: 1-4% concentration in serums or creams. Applied 1-2 times daily to target areas like forehead and crow's feet. |
| Administration | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. | Topical application only. Should be applied to clean skin. Often combined with other anti-aging peptides for synergistic effects. |
| Side Effects | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). | Generally well-tolerated topically. Rare reports of mild skin irritation or sensitivity. |
| Best For |